Advertisement

Chromatographia

, Volume 48, Issue 7–8, pp 555–560 | Cite as

High-performance liquid chromatographic assay for simultaneous determination of tramadol and its active metabolite in human plasma. Application to pharmacokinetic studies

  • M. A. Campanero
  • B. Calahorra
  • E. García-Quetglás
  • M. Escolar
  • J. Honorato
Originals

Summary

A sensitive liquid chromatographic assay for the quantitative determination of the opioid analgesic tramadol and its active metabolite is described. Fluconazole was used as internal standard. The assay involved a singletert-butyl methyl ether extraction and LC analysis with fluorescence detection. Chromatography was at 30°C pumping an isocratic mobile phase of acetonitrile-water (19∶81, v/v) containing 0.06M NaH2PO4 and 0.05M triethylamine, adjusted to pH 7.90, at 1 mL min−1 through a reversed-phase, 250×4 mm base-stable column. The limit of quantitation of tramadol and its active metabolite was 1 ng mL−1, only 0.5 mL plasma sample was required for the determination. The calibration curve was linear from 1–1000 ng mL−1. Intra and inter-day precision (C.V.) did not exceed 10%. Mean recoveries of 96.38% for tramadol and 96.62% forO-demethyltramadol with CVs of 0.43% and 1.46% were obtained. Applicability of the method was demonstrated by a pharmacokinetic study on normal volunteers who received 100 mg tramadol intravenously.

Key Words

Column liquid chromatography Tramadol andO-demethyl tramadol in plasma Pharmacokinetics 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    L. Poulsen, L. Arendt-Nielsen, K. Brosen, S. H. Sindrup, Clin. Pharm. Ther.60, 636 (1996).CrossRefGoogle Scholar
  2. [2]
    P. Dayer, L. Collart, J. Desmules, Drugs47(Suppl. 1), 3 (1994).CrossRefGoogle Scholar
  3. [3]
    American Society of Hearth-System Pharmacists, Inc.28:08.92, 1508 (1996).Google Scholar
  4. [4]
    R. B. Raffa, E. Friderchs, W. Reimann, R. P. Shank, E. E. Codd, J. L. Vaught, H. I. Jacoby, N. Selve, J. Pharmacol Exp. Ther.267, 331 (1993).Google Scholar
  5. [5]
    E. Frankus, E. Friderichs, S. M. Kim, G. Osterlon, Arznem-Forsch.28, 114 (1978).Google Scholar
  6. [6]
    R. Becker, W. Lintz, J. Chromatogr. B377, 213 (1986).Google Scholar
  7. [7]
    W. Lintz, H. Uragg, J. Chromatogr. B341, 65 (1985).Google Scholar
  8. [8]
    M. Merslavic, L. Zupancic-Kralj, J. Chromatogr. B693, 222 (1997).Google Scholar
  9. [9]
    W. Lintz, S. Erlacin, E. Frankus, H. Uragg, Arzem-Forsch.31, 1932 (1981).Google Scholar
  10. [10]
    B. Elsing, G. Blaschkel, J. Chromatogr. B612, 223 (1993).Google Scholar
  11. [11]
    W. D. Paar, P. Frankus, H. J. Dengler, J. Chromatogr. B686, 221 (1996).Google Scholar
  12. [12]
    M. Nobilis, J. Pastera, P. Anzenbacher, D. Svoboda, J. Kopecky, F. Perlik, J. Chromatogr. B681, 177 (1996).Google Scholar
  13. [13]
    F. Bressolle, M. Bromet-Petit, M. Audra, J. Chromatogr B686, 3 (1996).Google Scholar
  14. [14]
    R. Causon, J. Chromatogr. B689, 175 (1997).Google Scholar
  15. [15]
    H. Schütz, J. Clin. Chem. Clin. Biochem.17, 85 (1979).Google Scholar

Copyright information

© Friedr. Vieweg & Sohn Verlagsgesellschaft mbH 1998

Authors and Affiliations

  • M. A. Campanero
    • 1
  • B. Calahorra
    • 1
  • E. García-Quetglás
    • 1
  • M. Escolar
    • 1
  • J. Honorato
    • 1
  1. 1.Servicio de Farmacología Clínica, Clínica Universitiria de navarraUniversidad de NavarraPamplonaSpain

Personalised recommendations